Skip to content

Building Respiratory Support in East Africa Through High Flow Versus Standard Flow Oxygen Evaluation

Building Respiratory Support in East Africa Through High Flow Versus Standard Flow Oxygen Evaluation

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05754034
Acronym
BREATHE
Enrollment
1600
Registered
2023-03-03
Start date
2023-10-11
Completion date
2026-12-31
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Hypoxemia

Brief summary

Acute hypoxemia is common and deadly in resource variable settings. While studies in high income countries (HICs) have indicated a possible benefit to high flow oxygen as compared with standard flow oxygen, rigorous studies in low or lower middle income countries (LMICs) have not been performed. Studies in sepsis have demonstrated that interventions that improve outcomes in one context may actually be neutral or harmful in a different context. The goal of this study is to test whether high flow oxygen results in better outcomes for hypoxemic adult patients, as compared with standard flow oxygen, in five LMIC hospitals. The main questions it aims to answer are: 1. For hypoxemic adults in these LMIC study settings, does high flow oxygen or standard flow oxygen result in lower mortality? 2. What are the facilitators and barriers to using high flow oxygen in these settings? 3. Does high flow or standard flow oxygen use more oxygen? Participants will be randomized to receive either high flow oxygen through a large nasal cannula, or to receive standard flow oxygen, through nasal cannulas, face masks, or non-rebreather masks. Researchers will compare the outcomes for the two groups, to see if one group of patients has better outcomes than the other. The study will also examine how much oxygen is used by the two patient groups, as well as other factors relevant to the feasibility of implementation of high flow oxygen in these sites.

Interventions

OTHERStandard flow oxygen

oxygen delivered at standard flow rates via nasal cannula, facemask, or nonrebreather mask, with protocol to target SpO2 90-94%

humidified and heated oxygen delivered at high flow rates via nasal cannula, with protocol to target SpO2 90-94%

Sponsors

Wellcome Trust
CollaboratorOTHER
Beth Israel Deaconess Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age\>=18 years AND * admitted to a study site hospital within the 24 hours prior to screening AND * SpO2\<90% at time of first assessment OR * receiving oxygen at time of first assessment

Exclusion criteria

* imminent death (high clinical suspicion of death within 24 hours of admission) * patient or caregiver refusal of study participation * history of chronic respiratory failure (SpO2\<90% or oxygen dependence for at least three months) * anatomical factors precluding the use of nasal cannula * intubation or non-invasive ventilation by the clinical team prior to screening for the trial * known hypoxemia at transferring facility for \>48 hours * lack of availability of either SFO or HFO devices or supplies at the time of randomization.

Design outcomes

Primary

MeasureTime frameDescription
In-hospital mortalityDay 90Death between randomization and end of hospitalization

Secondary

MeasureTime frameDescription
90-day mortalityDay 90Death between randomization and 90 days
90-day functional statusDay 90Functional status 90 days after randomization, as measured by the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)
Need for mechanical ventilationDay 90Met objective criteria for need to escalate respiratory therapy to NIV or invasive ventilation, or escalated to NIV or mechanical ventilation
Days requiring oxygenDay 90Days requiring oxygen from randomization to end of hospitalization
ICU length of stayDay 90Total days in the ICU during hospitalization
Time to meeting criteria for need for escalation to either NIV or invasive ventilationDay 90Time to meeting objective clinical criteria for escalation to non-invasive ventilation or invasive ventilation
Time to escalation to either NIV or invasive ventilationDay 90Time to escalation to non-invasive ventilation or invasive ventilation
Hospital length of stayDay 90Days from randomization to hospital discharge or death

Other

MeasureTime frameDescription
Oxygen consumptionDay 90Total oxygen consumed during hospitalization

Countries

Kenya, Malawi, Rwanda

Contacts

Primary ContactElisabeth Riviello, MD, MPH
eriviell@bidmc.harvard.edu+1 617 447 5131
Backup ContactTheogene Twagirumugabe, MD, PhD
twagirumugabe@gmail.com+250 788 539 904

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026